Price movement over the last 24 hours
ADMA Biologics Inc vs iShares Russell 2000 ETF — how do they compare? ADMA Biologics Inc trades at $9.16 (market cap $2.13B), while iShares Russell 2000 ETF trades at $293.08. The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | IWM | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $300.45 |
52-Week Low | $7.60 | $214.95 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
IWM (iShares Russell 2000 ETF) trades at $298.90, up 0.46% with a bullish technical signal supported by moving averages. The ETF holds nearly 2,000 small-cap stocks and has gained 22.1% year-to-date, outperforming major indices. Recent news highlights small-cap strength amid shifting rate expectations, though key financial ratios remain undisclosed in current data.
Outlook remains positive given small-cap momentum and potential rate cuts, but risks include higher volatility and economic sensitivity. The ETF's diversification offers growth exposure, yet investors should weigh valuation concerns and market concentration against historical underperformance versus broad market indices over longer periods.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →